Stock analysts at HC Wainwright have revised their earnings estimates for ReWalk Robotics Ltd. (NASDAQ: RWLK) for the fiscal year 2023. In a recent research report, HC Wainwright analyst S. Ramakanth predicts that the medical device company will post earnings of ($0.38) per share for the year, down from their previous estimate of ($0.35) per share.

While HC Wainwright maintains a “Buy” rating on the stock, they have also lowered their price objective to $3.00. The consensus estimate for ReWalk Robotics’s full-year earnings in 2023 is ($0.35) per share.

The revised earnings forecast from HC Wainwright reflects the analysts’ expectations of a slight decrease in ReWalk Robotics’ financial performance for the fiscal year 2023. This could be due to various factors, such as market conditions or changes in the company’s business strategy. However, it is important to note that earnings estimates are subject to change and can be influenced by a variety of factors.

ReWalk Robotics is a medical device company that specializes in the design, development, and commercialization of robotic exoskeletons for individuals with mobility impairments or other medical conditions. Their products include the ReWalk Personal and ReWalk Rehabilitation exoskeletons, as well as the ReStore soft exo-suit for stroke rehabilitation. These innovative devices aim to improve the quality of life for individuals with spinal cord injuries or lower limb disabilities.

As with any investment, it is essential for investors to conduct their own research and consider various factors before making any decisions. The stock market is inherently unpredictable, and individual company performance can be influenced by a wide range of factors.